FDA Determines Regulatory Review Period for GALILEO INTRAVASCULAR RADIOTHERAPY SYSTEM Patent Extension

Summary

The US Food and Drug Administration (FDA) has officially confirmed the regulatory review period for the GALILEO INTRAVASCULAR RADIOTHERAPY SYSTEM, a medical device, in order to extend the patent, as required by law.